RecruitMe Clinical Trial

HVTN 130/HPTN 089: A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants (Harlem)
A Study to Test the Safety of Monoclonal Antibodies in HIV-uninfected Participants (ages 18-50) (Harlem)
Sponsor:DAIDS, NIAID, NIH
Enrolling:Male and Female Patients
Study Length:19 Months
Clinic Visits:11
Age Range:Between 18 and 50 years old
IRB Number:AAAS4083
Contact: HIV Studies: 212-305-2201 / hiv_studies@columbia.edu
Additional Study Information:

Antibodies are one of the natural ways that our bodies fight or prevent infection. We're testing an antibody to find out if it's safe, if they don't make people feel uncomfortable, how these study antibodies move throughout the body, and to measure antiviral activity. You cannot get HIV from the study antibody. First, request to be contacted by our study team. We'll follow up by asking you to complete a brief electronic prescreen questionnaire to find out if you meet basic study criteria. If you meet basic criteria, we'll invite you to our research site to review the study for which you may be eligible and possibly draw blood to find out if you meet additional medical criteria. You'll receive $75 for the screening visit. If you're eligible, consent to participate, and are assigned into Group 1, 2, or 3, you will receive IV infusions of the antibodies at 1 visit only for which you'll be compensated $200 for completing the visit. We'll also ask you to return to the research site another 10 times to complete follow up visits that require blood to be drawn for which you'll be compensated $75 for each visit. If you're eligible, consent to participate, and are assigned into Group 4, you'll receive IV infusions of the antibodies at 2 visits for which you'll be compensated $300 per visit. We'll also ask you to return to the research site another 13 times to complete follow up visits that require blood to be drawn for which you'll be compensated $75 per visit. Your participation will help end HIV by informing medical science and HIV prevention efforts.

Do You Qualify?
Are you between the ages of 18 to 50?YesNo
Are you HIV negative (HIV-)?YesNo
Are you available to attend scheduled study visits that last several hours?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
HIV Studies
Email: hiv_studies@columbia.edu
Phone: 212-305-2201